- Multiple hereditary exostosis (MHE), a rare genetic musculoskeletal disorder characterized by benign bone tumors, is gaining growing recognition in the European healthcare landscape due to advancements in genetic diagnostics and improved clinical surveillance across both pediatric and adult populations
- The rising demand for early diagnosis and patient-specific treatment approaches is primarily fueled by expanding rare disease registries, enhanced physician awareness, and active collaboration between patient advocacy groups and research institutions throughout Europe
- Germany dominated the Europe multiple hereditary exostosis market with the largest revenue share of 24.8% in 2024, supported by a robust healthcare infrastructure, well-developed rare disease networks, and the presence of specialized genetic research centers and clinical trial hubs
- Poland is expected to be the fastest growing country in the Europe multiple hereditary exostosis market during the forecast period due to significant improvements in public healthcare services, increased investment in rare disease diagnostics, and expanding access to advanced genetic screening programs
- Sessile segment dominated the Europe multiple hereditary exostosis market with a market share of 62.5% in 2024, driven by its broader base of bone attachment, leading to higher clinical prevalence and easier radiographic detection
